<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01603849</url>
  </required_header>
  <id_info>
    <org_study_id>pciHighRiskINCAN</org_study_id>
    <nct_id>NCT01603849</nct_id>
  </id_info>
  <brief_title>Prophylactic Cranial Irradiation in Patients With Lung Adenocarcinoma With High Risk of Brain Metastasis</brief_title>
  <acronym>PCI</acronym>
  <official_title>Randomized Phase II Trial of Prophylactic Cranial Irradiation in Patients With Lung Adenocarcinoma Clinical Stage IIIB and IV With High Risk of Brain Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Cancerologia de Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Cancerologia de Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lung cancer is the first cause of death among cancer patients. Non Small Cell lung cancer&#xD;
      (NSCLS) represents about 80-85% of the cases. Of this, about 80% presents with locally&#xD;
      advanced or metastatic disease. Important to mention the number of patients that progress or&#xD;
      recur in central nervous system (CNS). It has been reported that patients with&#xD;
      adenocarcinoma, who are under 60 years and with elevated carcinoembryonic antigen (CEA) are&#xD;
      in the highest risk to develop brain metastasis. In small cell lung cancer, treatment with&#xD;
      prophylactic cranial irradiation (PCI) is the standard of care in patients without&#xD;
      progression after locoregional or systemic treatment because the proven benefit in overall&#xD;
      survival (OS) and progression free survival (PFS). However, in NSCLC PCI has not been able to&#xD;
      prove any survival benefit, only in CNS PFS, probably because there is no trial, to our&#xD;
      knowledge, of PCI in NSCLC that include only the specific group of patients considered in&#xD;
      high risk of developing brain metastasis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:&#xD;
&#xD;
        1. To obtain a greater PFS and CNS PFS in patients with NSCLC treated with PCI after&#xD;
           locoregional or systemic treatment.&#xD;
&#xD;
        2. Evaluate the benefit in OS in the specific group of patients who are at increased risk&#xD;
           of developing brain metastasis&#xD;
&#xD;
        3. Evaluate quality of life and mental function before and after treatment with PCI and&#xD;
           compare it with patients in the observation group.&#xD;
&#xD;
      Methods: One hundred and twenty eight patients with locally advanced or metastatic (except&#xD;
      CNS metastasis) NSCLC will be included and randomized to receive either observation or PCI 25&#xD;
      Gy in 10 fractions Whole Brain Radiotherapy (WBRT) once the initial treatment has been&#xD;
      completed and progression of the disease ruled out.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">July 2020</completion_date>
  <primary_completion_date type="Actual">July 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence of brain metastases</measure>
    <time_frame>24 months</time_frame>
    <description>From the day of randomization to the date when brain metastasis develop if this is the case.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>24 months</time_frame>
    <description>From the day of randomization to the date of death if this is the case</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as per QLQ-C30</measure>
    <time_frame>12 months</time_frame>
    <description>a QLQ questionnaire from EORTC organization (spanish version) will be performed before, during and after PCI and will be compared with the observation group questionnaires.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mental function</measure>
    <time_frame>12 months</time_frame>
    <description>A mini mental status examination will be performed before, during and after PCI and will be compared with the observation group questionnaires</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>A Prophylactic Cranial Irradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will received PCI 25 Gy in 10 fractions WBRT 4 weeks after initial treatment in the absence of disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B Observation Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in this arm will be observed (not receiving WBRT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Prophylactic Cranial Irradiation</intervention_name>
    <description>Patients allocated to this arm will received treatment with whole brain radiotherapy 25 Gy in 10 fractions.</description>
    <arm_group_label>A Prophylactic Cranial Irradiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histologically proven advanced NSCLC (Stage IIIB or IV) including&#xD;
             wild-type, EGFR-mutated or ALK-rearrangements who received treatment and were without&#xD;
             progression at the end.&#xD;
&#xD;
          -  Above 18 years&#xD;
&#xD;
          -  General status with a Karnofsky &gt;80%&#xD;
&#xD;
          -  Eastern Cooperative Group (ECOG) ≤2&#xD;
&#xD;
          -  Negative CNS MRI at the beginning of any treatment&#xD;
&#xD;
          -  Carcinoembryonic antigen &gt; 20 pg&#xD;
&#xD;
          -  Hepatic and hematic cytology test within normal range&#xD;
&#xD;
          -  Adequate renal function&#xD;
&#xD;
          -  Those who accepted to participate in the study and who sign the letter of informed&#xD;
             consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with another type of cancer&#xD;
&#xD;
          -  Patients who refuse participate in the protocol&#xD;
&#xD;
          -  General status with a Karnofsky &lt;80%&#xD;
&#xD;
          -  Eastern Cooperative Group (ECOG) &gt;2&#xD;
&#xD;
          -  Previous treatment with WBRT&#xD;
&#xD;
          -  Previous treatment with chemotherapy&#xD;
&#xD;
          -  Disease progression after initial treatment, either chemotherapy or chemoradiotherapy&#xD;
             depending the case.&#xD;
&#xD;
          -  CNS metastasis at diagnosis&#xD;
&#xD;
          -  Abnormal laboratory test that interfere with chemotherapy or TKI administration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oscar MD Arrieta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Cancerologia, Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Nacional de Cancerología</name>
      <address>
        <city>Mexico City</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>April 17, 2012</study_first_submitted>
  <study_first_submitted_qc>May 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2012</study_first_posted>
  <last_update_submitted>July 28, 2020</last_update_submitted>
  <last_update_submitted_qc>July 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Cancerologia de Mexico</investigator_affiliation>
    <investigator_full_name>Oscar Gerardo Arrieta Rodríguez</investigator_full_name>
    <investigator_title>Head of Lung Cancer Clinic</investigator_title>
  </responsible_party>
  <keyword>Prophylactic Cranial Irradiation</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>Non Small Cell Lung Cancer</keyword>
  <keyword>Carcinoembryonic Antigen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma of Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

